Transcription factor E2F1 (E2F1) (E2F1)

Transcription factor E2F1 (E2F1) is a member of the E2F family that plays a crucial role in the control of the cell cycle and the action of tumor suppressor proteins (UniProt Q01094). It primarily mediates the G1/S phase transition by activating the transcription of genes required for DNA replication, such as dihydrofolate reductase and DNA polymerase alpha (NCBI Gene 1869). The activity of E2F1 is tightly regulated by the retinoblastoma protein (pRb); in its hypophosphorylated state, pRb binds to E2F1 and represses its transactivation domain (PubMed: 19147076). Dysregulation of the pRb/E2F1 pathway is a hallmark of many cancers, where excessive E2F1 activity drives aberrant cell proliferation and tumor progression (Expert Opin Ther Targets, 2009). Interestingly, E2F1 also functions as a potent inducer of apoptosis in response to DNA damage or oncogenic stress, acting through both p53-dependent and independent pathways (Nature Reviews Cancer, 2002). Therapeutic targeting of E2F1 involves small molecule inhibitors like HLM006474, which aim to block its DNA-binding activity, as well as indirect modulation via CDK4/6 inhibitors like Palbociclib to restore pRb-mediated control. Despite its potential, targeting E2F1 remains challenging due to its essential role in normal tissue homeostasis and its dual role in promoting both survival and death.

Other names

E2F-1Retinoblastoma-associated protein 1RBAP-1Retinoblastoma-binding protein 3RBBP-3pRB-binding protein 3PBR3

Direct inhibition of E2F1 transcriptional activity by disrupting DNA binding or indirect modulation of the pRb/E2F1 complex via CDK4/6 inhibition to prevent E2F1 release.